Brief Introduction
Dr. Yi-Ping Hung is a medical oncologist at Taipei Veterans General Hospital and an Assistant Professor at National Yang Ming Chiao Tung University. His clinical and research interests focus on gastrointestinal malignancies, including pancreatic, gastric, esophageal, hepatobiliary, and colorectal cancers, with emphasis on systemic therapy, cancer immunotherapy, biomarkers, and precision oncology. He completed postdoctoral research at Stanford University and is actively involved in clinical trials and translational cancer research.
Specialty
- Gastrointestinal Oncology (pancreatic, gastric, esophageal, hepatobiliary, and colorectal cancers)
- Medical Oncology
- Cancer Immunotherapy
- Precision Oncology
- Clinical Hematology
Education
- 2021: PhD, Institute of Clinical Medicine, National Yang-Ming University, Taiwan
- 2005: MD, School of Medicine, National Taiwan University, Taipei, Taiwan
Experience
- 2025 – Present: Chief, Division of Medical Ethics and Quality Management, Center of Quality Management, TVGH
- 2022 – Present: Executive Secretary, Human Research Protection Center (HRPC), TVGH
- 2021 – Present: Assistant Professor, School of Medicine, National Yang Ming Chiao Tung University
- 2014 – Present: Attending Physician, Division of Medical Oncology, Department of Oncology, TVGH
- 2019 – 2020: Postdoctoral Research, Shriram Center, Stanford University
- 2011 – 2014: Fellowship, Hematology and Oncology, TVGH
- 2008 – 2011: Resident, Department of Internal Medicine, TVGH
Selected Publications
- Hung YP, Lee PC, Chang YH, et al. Hepatic Events During Immune Checkpoint Inhibial Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic Areas. Aliment Pharmacol Ther. 2025;61(3):501-512.
- Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP, et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N Engl J Med. 2024;391:1159-1162.
- Chung SY*, Hung YP*, Pan YR, et al. Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. Biomedicines. 2021;9:885.
- Hung YP, Shao YY, Lee JM, et al. Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. J Chin Med Assoc. 2021;84(2):144-150.
- Pan YR, Wu CE, Wang YC, et al.; Hung YP. Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. Clin Transl Immunology. 2020;9(7):e1145.
- Lu LC, Hsu C, Shao YY, et al.; Hung YP. Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma. Liver Cancer. 2019;8(6):480-490.
- Fang WL, Lan YT, Huang KH, et al.; Hung YP. Clinical significance of circulating plasma DNA in gastric cancer. Int J Cancer. 2016;138(12):2974-2983.
- Chou WC, Lin PH, Yeh YC, et al.; Hung YP. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. Int J Biol Sci. 2016;12(12):1523.
- Wang JP, Wu CY, Hwang IH, et al.; Hung YP. How different is the care of terminal pancreatic cancer patients in inpatient palliative care units and acute hospital wards? BMC Palliat Care. 2016;15:1-8.
- Wang JP, Wu CY, Yeh YC, et al.; Hung YP. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget. 2015;6(20):18162-18182.